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Hippuric acid nanocomposite enhances doxorubicin and oxaliplatin-induced 
cytotoxicity in MDA-MB231, MCF-7 and Caco2 cell lines. 
 
ABSTRACT 
Background: The aim of the current study is to design a new nanocomposite for inducing 
cytotoxicity of doxorubicin and oxaliplatin toward MDA-MB231, MCF-7, and Caco2 cell 
lines. A hippuric acid (HA) zinc layered hydroxide (ZLH) nanocomposite was synthesized 
under an aqueous environment using HA and zinc oxide (ZnO) as the precursors. Methods: 
The hippuric acid nanocomposite (HAN) was prepared by the direct reaction of a HA 
solution with an aqueous suspension of ZnO. Results: The basal spacing of the 
nanocomposite was 21.3 Å, which is average of four harmonics at 2θ = 8.32°, 12.50°, 16.68°, 
and 20.84°. This result indicates that the hippurate anion was successfully intercalated into 
the interlayer space of ZLH. The combinations of HAN with chemotherapy (drugs) has 
inhibited the cell growth of the MDA-MB231, MCF-7, and Caco2 cancer cells when 
compared to drugs alone. An IC50 value for the combination of HAN with doxorubicin 
toward MCF-7 is 0.19 ± 0.15 µg/mL and toward MDA-MB231 is 0.13 ± 0.10 µg/mL. 
Similarly, the IC50 for the combination of HAN with oxaliplatin toward Caco2 is 0.24 ± 0.11 
µg/mL. In the antiproliferative results, the equal combination of HAN (0.5 µg/mL) with 
doxorubicin (0.5 µg/mL) has reduced the cell proliferation in MCF-7 and MDA-MB- 231 
cells into 37.3% and 17.6%, respectively after 24 hours. Similarly, the antiproliferation 
percentage for equal combination HAN with oxaliplatin (5.00 µg/mL) toward Caco2 is 72.7% 
after 24 hours. Conclusion: The resulting combination HAN with drugs has exhibited higher 
inhibition in cells growth in all cancer cell lines 
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